A0524 Time to subsequent chemotherapy with capivasertib (capi) + abiraterone (abi) versus placebo (pbo) + abi in patients (pts) with PTEN deficient metastatic hormonesensitive prostate cancer (mHSPC): CAPItello-281

European Urology 2026

View at publisher
Authors: N. Clarke, D.J. George, M. De Santis, H. Uemura, A.P. Fay, N. Karadurmus, M. Kwiatkowski, C. Alvarez-Fernandez, S. J. Jiang, M. Sotelo, M. Özgüroglu, G. Roubaud
+8 more D. Castellano, M. Sugimoto, L. Shi, V. Talreja, M. Yeste-Velasco, A.R. Lima, C. Gresty, K. Fizazi
DOI: 10.1016/s0302-2838(26)00576-2
Cited by: 1

Fields of Study & Subjects

Prostate Cancer Treatment and Research PI3K/AKT/mTOR signaling in cancer Prostate Cancer Diagnosis and Treatment

Publication details

Journal / source
European Urology
Publisher
Elsevier BV
Volume
89
Pages
S1–S2
Publication date
13 February 2026
Language
EN